Document is current
Any future updates will be listed below
-
Authors
Xia, Yuan https://orcid.org/0000-0002-8061-4955
Wang, Li
Shen, Xuxing
Xu, Ying
Xu, Wei
Li, Jianyong
Fan, Lei
Chen, Lijuan https://orcid.org/0000-0002-6497-1194
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82370205)
Social Development Project of Jiangsu Science and Technology Plan (BE2022810)
Key Program of Taizhou School of Clinical Medicine of Nanjing Medical University (TZKY20220310)
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 16 September 2024
First Online: 27 September 2024
Declarations
:
: The retrospective clinical study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of the First Affiliated Hospital of Nanjing Medical University Ethics Committee: (1) No. 2019-MD-512; Title: Safety and efficacy of anti-CD19 CAR-T treatment in DLBCL Subjects; Date of approval: January 15, 2020; (2) No. 2019-SR-335; Title: A study on the efficacy and safety of CD20 CAR-T for the treatment of B-cell lymphoma; Date of approval: August 28, 2019. Written informed consents were obtained from all the patients before enrollment. All animal care and experimental procedures were complied with the standards of Animal Welfare for the Care and Use of Laboratory Animals of Nanjing Medical University, and were approved by Institutional Animal Care and Use Committee (IACUC) of Nanjing Medical University (No. 2201014. Title: Effect of mesenchymal stem cells on hematopoietic injury after CAR-T therapy in mice. Date of approval: January 11, 2022).
: All authors confirm their consent for publication.
: The authors declare no competing interests in this work.
